Rufinamide
From Wikipedia, the free encyclopedia
Rufinamide
|
|
Systematic (IUPAC) name | |
1-[(2,6-difluorophenyl)methyl]triazole-4-carboxamide | |
Identifiers | |
CAS number | |
ATC code | N03 |
PubChem | |
Chemical data | |
Formula | C10H8F2N4O |
Mol. mass | 238.194 |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Rufinamide is an anticonvulsant medication.
Used in combination with other medication and therapy to treat Lennox-Gastaut syndrome and various other seizure disorders, Rufinamide, a triazole derivative, was developed in 2004 by Novartis Pharma, AG, and is manufactured by Eisai.